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The inflammatory bowel diseases (IBD), which include mainly Crohn’s disease (CD) and
ulcerative colitis (UC), are common chronic inflammatory conditions of the digestive system.
The diagnosis of IBD relies on the use of a combination of factors including symptoms,
endoscopy and levels of serum proteins such as C-reactive protein (CRP) or faecal calpro-
tectin. Currently there is no single reliable biomarker to determine IBD. Galectins are a fam-
ily of galactoside-binding proteins that are commonly altered in the circulation of disease
conditions such as cancer and inflammation. This study investigated serum galectin levels
as possible biomarkers in determining IBD and IBD disease activity. Levels of galectins-1,
-2, -3, -4, -7 and -8 were analysed in 208 samples from ambulant IBD patients (97 CD, 71
UC) patients and 40 from healthy people. Disease activity was assessed using Harvey-
Bradshaw Index for CD and simple clinical colitis activity index for UC. The relationship of
each galectin in determining IBD and IBD disease activity were analysed and compared
with current IBD biomarker CRP. It was found that serum level of galectin-1 and -3, but not
galectins-2, -4, -7 and -8, were significantly higher in IBD patients than in healthy people. At
cut-off of 4.1ng/ml, galectin-1 differentiated IBD from healthy controls with 71% sensitivity
and 87% specificity. At cut-off of 38.5ng/ml, galectin-3 separated IBD from healthy controls
with 53% sensitivity and 87% specificity. None of the galectins however were able to distin-
guish active disease from remission in UC or CD. Thus, levels of galectins-1 and -3 are sig-
nificantly elevated in both UC and CD patients compared to healthy people. Although the
increased galectin levels are not able to separate active and inactive UC and CD, they may
have the potential to be developed as useful biomarkers for IBD diagnosis either alone or in
combination with other biomarkers.
Introduction
Inflammatory bowel diseases (IBD) are common chronic inflammatory conditions of the
digestive system. IBD mainly include Crohn’s disease (CD), which can affect any part of the
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digestive tract, and ulcerative colitis (UC), which affects only the colon[1]. Both CD and UC
typically cause symptoms of diarrhoea, abdominal pain, fatigue and weight loss[1]. The preva-
lence of IBD in Western countries is high and a recent Scottish study estimated a prevalence of
784/ 100, 000 population[2]. The diagnosis of IBD usually relies on a combination of symp-
toms, laboratory tests such as C-reactive protein (CRP), faecal calprotectin (FC) and endo-
scopic evaluation. Endoscopic evaluation is considered the gold standard and at present, there
are no simple blood markers which accurately diagnose IBD[3].
IBD typically follow a relapsing-remitting pattern with periods of disease activity inter-
spersed with quiescent disease[1]. IBD disease activity in clinical practice is often assessed in a
composite manner by (i) evaluation of symptoms using validated indices such as the Crohn’s
disease activity index (CDAI) or the Harvey-Bradshaw index (HBI) for CD, and the simple
clinical colitis activity index for UC; (ii) assessment of biomarkers such as C-reactive protein
(CRP) or faecal calprotectin (FC) and (iii) endoscopic evaluation[3]. Endoscopic assessment is
considered the gold standard for assessment of disease activity but repeated endoscopy is
impractical, expensive and associated with poor patient acceptance and a potential for compli-
cations. CRP is currently the most used non-invasive serum IBD biomarker in clinic. How-
ever, CRP determination [4] is limited by poor specificity and sensitivity as (i) CRP level is
altered in other acute inflammatory conditions in addition to CD and UC and (ii) up to 25%
of patients, who have demonstrable disease activity determined by endoscopy have normal
CRP values[5]. FC determination has far greater accuracy for detecting intestinal inflamma-
tion than CRP[6] but it requires collection of faecal sample which is cumbersome and has poor
patient acceptability[7]. Thus, there is a need for more accurate and non-invasive biomarkers
for establishing disease activity in IBD.
Galectins are a family of 15 (so far) mammalian galactoside-binding proteins that share a
consensus amino acid sequence in their carbohydrate recognition domains (CRDs)[8]. Based
on their structural differences, galectin family members are classified into three subgroups of
proto-, chimeric- and tandem-repeat-types. The prototype galectins include galectins-1, 2, 5, 7,
10, 11, 13, 14 and 15, each containing a single CRD in the polypeptide sequences and often
identified as non-covalently linked homodimer. The chimera-type galectin, which has only
one member galectin-3, is composed of an unstructured non-lectin domain linked to a CRD
and can form as multiple homotypic forms such as a pentamer. The tandem-repeat-type galec-
tins include galectin-4, 6, 8, 9 and 12, each containing two different CRDs close to each end of
the single polypeptide chain[9].
Galectins are widely expressed by human cells, in particular epithelial and immune cells.
Several galectin members including galectins-1, -2, -3, -4 and -8 [10] are known to be
expressed by the human intestinal epithelium[11, 12]. A large body of evidence have reported
important roles of these galectins in colorectal cancer development, progression and metastasis
(e.g. tumor transformation, cancer cell adhesion, invasion, migration and angiogenesis) by
galectin interaction with a number of galactose-terminated glycans[13]. Serum levels of galec-
tins such as galectins-2,-3, -4 and -8 are significantly higher in colon cancer patients than in
healthy people [14] and promotes circulating tumour cell haematogenous dissemination in
metastasis[14–17]. Interactions of galectins with galactose-terminated glycans on cell surface
have also been implicated in the pathogenesis of IBD by induction of T cell apoptosis and NF-
kappa B signaling [18–20], [19, 21]. Level of serum galectin-3 was reported to be higher in IBD
patients compared to healthy controls[22]. However, it is not known whether levels of any
other galectin members are also altered in the circulation of IBD patients and whether serum
galectins could be used as potential biomarkers for determining IBD and disease activity.
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In this study, we compared the serum levels of galectins-1, -2–3, -4, -7 and -8 in patients
with UC, CD and healthy people and analyzed the relationship of galectin levels with disease
activity in IBD patients.
Materials and methods
Materials
Recombinant human galectins-1, -2, -3, -4, -7 and -8, antibodies against human galectins-1, -2,
-3, -4, -7 and -8 and biotinylated antibodies against human galectins-1, -2, -3, -4, -7 and -8 were
obtained from R&D Systems (Abingdon, UK). ExtrAvidin peroxidase, FAST OPD and bovine
serum albumin were from Sigma-Aldrich (Dorset, UK).
Serum samples
Serum samples were obtained from a cross-sectional study of ambulant patients attending a
specialist IBD clinic at the Royal Liverpool University Hospital. A total of 168 samples from
IBD (including 97 from CD and 71 from UC) patients and 40 from healthy people were
obtained. Ethical approval was obtained from the Liverpool Regional Ethics Committee. Writ-
ten informed consent was obtained from all participants and the study population was com-
prised of adults over the age of 18. The diagnosis of IBD was established using conventional
clinical, endoscopic and radiological criteria. All patients were eligible for inclusion excepting
patients with an ostomy. Baseline details including disease phenotype, disease duration, smok-
ing status, concurrent medications, prior surgical history and HBI for Crohn’s disease and
SCCAI for ulcerative colitis were collected on the day of enrolment. The HBI is a 5-item index
used to assess disease activity in CD with a score�4 indicating remission, scores of 5–7, 8–16
and>16 indicating mild, moderate and severe disease[23]. The SCCAI includes 6 variables
with a score of�2 indicating remission, scores of 3–5, 6–11 and�12 indicating mild, moder-
ate and severe disease[24]. Laboratory tests were conducted as part of routine clinical care and
included full blood count, renal and liver function tests, C-reactive protein (CRP) measure-
ment. We investigated the ability of CRP to distinguish active disease from remission using a
threshold of CRP�5mg/L, as described previously [25].
Determination of serum levels of galectins
Serum levels of galectins-1, -2, -3, -4, -7 and -8, to which adequate capture and detection anti-
bodies and recombinant galectins are available commercially for sandwich galectin ELISA,
were determined by sandwich ELISA as described in our previous study[14]. Briefly, high-
binding 96-well plates were coated with anti-galectin antibody at 2.5 μg/mL in coating buffer
(15 mM Na2CO3 and 17 mM NaHCO3, pH9.6) overnight at 4˚C. The plate was washed with
washing buffer (0.05% Tween-20 in PBS) and incubated with blocking buffer (1% bovine
serum albumin in PBS) for 1 hr at room temperature. Serum samples (1:2 or 1:5 dilution in
PBS) or standard recombinant galectins were introduced to the plates for 2 hrs. After two
wishes with PBS, biotinylated anti-galectin antibody (1.25 μg/mL in blocking buffer) was
applied for 1 hr at room temperature before application of ExtrAvidin peroxidase (1:10,000
dilution in blocking buffer) for 1 hour. Following two washes with PBS, the plates were devel-
oped with SigmaFAST OPD for 10 minutes. The reaction was stopped by adding 4 mol/L sul-
furic acid before the absorbance was read at 492 nm by a microplate reader.
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Statistical analysis
Differences between the levels of each galectin in UC, CD and healthy people were analysed by
Mann-Whitney U test. Patient demographics are summarised as mean (SD) or median (IQR)
for continuous variables and frequency (%) for categorical variables. Mean and median serum
galectin levels were calculated to account for inter-individual variability in serum galectin lev-
els. The difference between remission and active disease groups was analysed using Mann-
Whitney test. Receiver operating characteristic (ROC) curves were constructed to assess the
independent ability of galectins to discriminate between patients with and without clinical
remission, using the area under the ROC curve (AUROC). The optimal cut-off point was cal-
culated by minimising the distance between the ROC curve and the upper left hand corner of
the plot. Analysis was conducted for all patients combined and then by diagnosis. Similar anal-
yses were conducted to examine the correlation between CRP and disease activity. All analysis
was performed using Stata v13 software (State Statistical Software: Release 12. College Station,
TX: StataCorp LP), p< 0.05 is considered significant in all cases.
Results
A total of 208 serum samples (40 from healthy people, 97 from CD and 71 from UC patients)
were included in the study. The baseline characteristics of the included IBD patients and
healthy people are summarised in Table 1. Of the IBD patients, 70 (72.2%) CD patients and 30
(43.3%) UC patients were in clinical remission as defined by HBI�4 or SCCAI�2.
Serum galectin levels in healthy people and IBD patients
Serum levels of six galectin members were analysed. Among these galectin members, two
galectins, galectin- 1 and -3 were found to have significantly higher levels in IBD patients com-
pared to the healthy controls. When galectin levels were compared separately between UC and
CD with healthy controls, significantly higher levels of galectin-1 (p = 0.0001 and 0.0003) and
galectin 3 (p = 0.0003 and 0.0001, respectively) were found in UC and CD respectively
(Table 2). Serum levels of galectin-2, -4, -7 and -8 showed no significant differences in UC and
CD than in the healthy controls, although their levels in IBD patients were numerically higher.
We next analysed the optimal concentration of galectins-1 and -3 that could distinguish IBD
from healthy controls. At a cut-off of 4.1ng/ml, galectin-1 differentiated IBD from healthy con-
trols with 71% sensitivity and 87% specificity. At a cut-off of 38.5ng/ml, galectin-3 differenti-
ated IBD from healthy controls with 53% sensitivity and 87% specificity. Finally, we analysed
serum levels of galectins-1, -2, -3, -4, -7, and -8 according to disease location (S1 File: S1-S6
Tables), disease duration (S1 File: S7-S12 Tables) and concomitant medications (S1 File:
S13-S18 Tables). No significant differences in median galectin values across the variables was
observed in any galectin member (S1 File: S1 to S18 Tables). As the sample size in each sub-
group in this study was small, future studies with larger sample numbers would help to further
clarify this conclusion.
Serum galectins in active and inactive IBD
We next analysed the relationship of levels of galectin members in active and inactive CD and
UC. None of the serum galectins showed significantly different in active UC and CD group
compared to UC (Table 3) and CD (Table 4) groups in remission. When serum CRP levels
were examined, significantly higher CRP was seen in patients with both active UC (P = 0.047,
Table 3) and CD (P = 0.047, Table 4) compared to patients in remission. We also analysed
serum galectin levels according to the clinical severity of disease activity (remission, mild,
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moderate or severe). We did not identify an association between serum galectin levels and
increasing disease severity (S1 File: S19-S24 Tables).
We then analysed if a combination of CRP with serum galectin-1 or -3 was better than
either marker on its own in determining disease activity in UC and CD (Table 5). CRP in com-
bination with either galectin-3 was able to distinguish active disease from remission in both
UC (P = 0.0219) and CD (0.0056). However, the combination of galectin-3 with CRP was no
better than CRP alone in distinguishing active disease from remission (p = 0.4150 from chi-
square test comparing AUCs). In contrast to galectin-3, a combination of galectin-1 and CRP
was unable to distinguish active disease from remission in both UC (P = 0.39) and UC
((P = 0.11). We then computed receiver operating characteristic (ROC) analysis of CRP alone
or in a combination of galectins-1 and -3 and CRP in active and inactive UC and CD
(Table 6). This combination did not show any significant improvement than CRP alone in dis-
tinguishing active from inactive disease.
Table 1. Baseline characteristics of the IBD patients and control healthy people.
Controls (n = 40) Crohn’s disease (n = 97) Ulcerative colitis (n = 71)
Age, mean (SD), years 48.8 (15.6) 40.9 (15.0) 45.1 (18.7)
Sex Male 16 (40.0) 36 (37.1) 33 (46.5)
Female 21 (52.5) 61 (62.9) 38 (53.5)
Smoking Current 5 (12.5) 25 (25.8) 12 (16.9)
Ex 8 (20.0) 18 (18.6) 18 (25.4)
Never 11 (27.5) 54 (55.7) 41 (57.8)
Missing 16 (40.0)
Disease location Colonic: 26 (26.8) Proctitis: 14 (19.7)
Ileal: 34 (35.1) Left-sided: 37 (52.1)
Ileocolonic: 27(27.8) Pancolitis: 20 (28.2)
Perianal: 25 (25.8%)
Disease duration (years) <1 8 (8.3) 7 (9.9)
1 to 5 15 (15.5) 22 (31.0)
5 to 10 18 (18.6) 40 (56.3)
>10 49 (50.5) 0 (0)
Missing 7 (7.2) 2 (2.8)
Previous surgery 35 (36.1) 0
Medications 5-ASA 26 (26.8) 58 (81.7)
Thiopurines 45 (46.4) 19 (26.8)
Methotrexate 2 (2.1) 1 (1.4)
Anti-TNF agent 19 (19.6) 5 (7.0)
Corticosteroids 6 (6.2) 9 (12.7)
Disease activity Active 27 (27.8) 41 (57.8)
Remission 70 (72.2) 30 (42.3)
C-reactive protein (mg/L)
>5 29 (29.9) 21 (29.6)
�5 17 (100) 51 (52.6) 45 (63.4)
Missing 17 (17.5) 5 (7.0)
Categorical variables: values are number (%)
https://doi.org/10.1371/journal.pone.0227306.t001
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Discussion
In this study, we analysed serum levels of galectins-1, -2, -3, -4, -7 and -8 in IBD patients and
healthy controls and investigated their value in determining IBD disease activity. It was found
that among these six galectins, galectin-1 and -3 both showed significantly higher serum levels
in UC and CD patients than in healthy people.
The intestinal epithelium harbours a number of galectin members and several of them are
known to be altered in disease conditions in particularly cancer. Changes of the expression of
galectins-1, -3, -4 and -9 in the inflamed tissues of IBD patients were reported previously[26].
Galectin profile analysis at mRNA level with biopsies from patients was able to distinguish
IBD from other intestinal inflammatory disorders such as coeliac disease and potentially to
also distinguish IBD from active form from quiescent ones[26]. Serum level of galectin-3 was
reported in an early study to be higher in IBD patients irrespective of their disease activity[22]
but no systematic comparison of the serum levels of galectin members has been done previ-
ously in IBD patients. The results in this study shows that levels of galectin-1 and -3, but not
Table 2. Galectin levels in healthy controls, UC and CD patients.
Controls
(n = 40)
Crohn’s disease (n = 97) Ulcerative colitis (n = 71) All IBD
(n = 168)
Gal-1
N 15 81 61 142
Mean (SD), ng/ml 6.2 (14.2) 42.8 (194.8) 51.7 (154.1) 46.6 (177.9)
Median (range), ng/ml 0.7 (0, 48.1) 7.5 (0.3, 1300) 11.9 (0, 815.9) 9.2 (0,1300)
P value 0.0001 0.0002 0.0001
Gal-2
N 20 87 66 153
Mean (SD), ng/ml 177.7 (616.5) 1068.2 (6229.7) 2628.6 (12845.9) 1741.3 (9650.1)
Median (range) 0.6 (0, 2669.3) 0.1 (0, 56371.4) 0 (0, 99546.4) 0.05 (0, 99546.4)
P value 0.6517 0.7962 0.7163
Gal-3
N 23 96 70 166
Mean (SD), ng/ml 22.0 (22.1) 49.1 (38.8) 55.3 (53.5) 51.7 (45.5)
Median (range), ng/ml 14.9 (0, 96.4) 42.1 (0, 282.1) 37.4 (0.7, 276.2) 41.7 (0, 282.1)
P value 0.0003 0.0001 <0.0001
Gal-4
N 23 88 71 159
Mean (SD), ng/ml 35.7 (58.0) 45.2 (122.6) 180.0 (989.7) 105.4 (668.4)
Median (range),ng/ml 0 (0, 185.5) 0 (0, 868) 0 (0, 8015) 0 (0, 8015)
P value 0.9072 0.8028 0.8403
Gal-7
N 14 70 55 125
Mean (SD), ng/ml 132.2 (163.6) 59.2 (138.7) 52.4 (154.8) 56.2 (145.4)
Median (range), ng/ml 60.1 (0, 466.3) 0 (0, 764.8) 0 (0, 859.7) 0 (0, 859.7)
P value 0.0350 0.1205 0.0574
Gal-8
N 18 93 69 162
Mean (SD), ng/ml 19.4 (31.0) 48.3 (96.6) 100.7 (313.5) 70.6 (218.0)
Median (range), ng/ml 4.7 (0, 104.2) 3.5 (0, 578.5) 18.1 (0, 2549.0) 7.3 (0, 2549.0)
P value 0.103 0.1607 0.4197
https://doi.org/10.1371/journal.pone.0227306.t002
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galectins-2, -4, -7 and -8, are significantly elevated in the circulation of IBD patients. The
increased levels of galectin-1 or -3 however could not separate active and inactive forms of UC
and CD. As an exploratory assessment for any indication of increased discrimination, a combi-
nation of CRP with galectins1 and 3 was further analysed but neither galectins-1 nor -3 were
unable to provide additive sensitivity of CRP in distinguishing active disease from remission.
Although further studies with larger sample size are needed to confirm this conclusion, it is
possible that the increase in serum galectins might represent an early event in the inflamma-
tory cascade and not subsequently rise further with increase of disease activity. The recent
reports showing that several galectin members play key pathogenic roles in animal models of
colitis[27] and galectin-3 caused macrophage activation in the induction phase of colitis in a
dextran sodium sulphate animal model of colitis[28] are in line with this possibility.
The increased level of serum galectin-3 in IBD patients found in this study is in agreement
with an early report showing higher serum galectin-3 level in IBD patients, irrespective of their
disease activity, compared with healthy people[22]. It is noted that a recent study by Cibor et al
reported significant elevation of serum level of galectin-3-binding protein (Gal-3BP), but not
galectin-3 itself, in IBD patients[29]. The much lower median serum galectin-3 level in healthy
people (7.1ng/ml) reported in the Cibor study than in this (22.0ng/ml) and a few other studies
Table 3. Galectin levels in patients with active and inactive UC.
UC only P value
SCCAI�2 SCCAI >2 All
Galectin 1
N 25 36 61
Mean (SD), ng/ml 104.9 (232.5) 14.8 (14.3) 51.7 (154.1)
Median (range), ng/ml 13.1 (0.2, 815.9) 10.5 (0, 48.9) 11.9 (0, 815.9) 0.4545
Galectin 2
N 25 41 66
Mean (SD), ng/ml 2078.7 (6474.6) 2964.0 (15578.7) 2628.6 (12845.9)
Median (range), ng/ml 0.1 (0, 29589.9) 0 (0, 99546.4) 0 (0, 99546.4) 0.3704
Galectin 3
N 30 40 70
Mean (SD), ng/ml 46.3 (43.1) 62.0 (60.0) 55.3 (53.5)
Median (range), ng/ml 28.3 (7.2, 186.4) 47.1 (0.7, 276.2) 37.4 (0.7, 276.2) 0.2353
Galectin 4
N 30 41 71
Mean (SD), ng/ml 122.4 (457.6) 222.1 (1248.2) 180.0 (989.7)
Median (range), ng/ml 0 (0, 2494.7) 0 (0, 8015) 0 (0, 8015) 0.4965
Galectin 7
N 21 34 55
Mean (SD), ng/ml 97.7 (226.6) 24.4 (77.4) 52.4 (154.8)
Median (range), ng/ml 0 (0, 859.7) 0 (0, 439.4) 0 (0, 859.7) 0.1672
Galectin 8
N 29 40 69
Mean (SD), ng/ml 134.7 (468.5) 76.1 (110.9) 100.7 (313.5)
Median (range), ng/ml 19.7 (0, 2549.0) 13.5 (0, 403.5) 18.1 (0, 2549.0) 0.6183
CRP
N 28 38 66
Mean (SD), mg/L 4.8 (14.5) 7.3 (12.5) 6.3 (13.3)
Median (range), mg/L 0 (0, 56) 0 (0, 55) 0 (0, 56) 0.0470
https://doi.org/10.1371/journal.pone.0227306.t003
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[30] indicates that bigger cohorts of patients may be needed in future studies to clarify the
discrepancy.
It is known that several galectin members including galectin-3[31] and galectin-1 [32, 33]
can interact with cell surface glycans and induce endothelium, epithelium or T cell secretion of
pro-inflammatory cytokines. For example, galectin-3 interaction with cell surface CD146
(MCAM) on vascular endothelial cells enhances endothelial secretion of IL-6, G-CSF and
GM-CSF [34]. Interaction of galectin-1 with intestinal epithelial cells in the presence of TNFα,
IL-13 or IL-5 was shown to enhance epithelial secretion of IL-10, IL-25, and TGF-β1[32]. The
presence of higher concentrations of galectin-1 caused significant increase of Il-10 secretion
from CD4(+) and CD8(+) T-cells[33]. As the chronic inflammatory condition in IBD is closely
associated with cytokines[35], an increased secretion of those pro-inflammatory cytokines by
circulating galectins-1 and -3, as a result of its elevated level in IBD, may play a role in disease
initiation and progression. Moreover, an increased circulation of galectins may themselves
have an impact on the pathogenesis and progression of IBD. Indeed, galectin-1 interaction
with intestinal epithelial cells was altered in the presence of inflammatory stimuli and
Table 4. Galectin levels in patients with active and inactive CD.
CD only P value
HBI�5 HBI >5 All�
Galectin 1
N 60 20 81
Mean (SD), ng/ml 52.6 (225.7) 15.1 (18.8) 42.8 (194.8)
Median (range), ng/ml 7.5 (0.3, 1300) 9.4 (0.6, 66.0) 7.5 (0.3, 1300) 0.5938
Galectin 2
N 64 22 87
Mean (SD), ng/ml 1336.6 (7226.3) 336.0 (1198.4) 1068.2 (6229.7)
Median (range), ng/ml 0.2 (0, 56371.4) 0.1 (0, 5545.4) 0.1 (0, 56371.4) 0.6338
Galectin 3
N 69 26 96
Mean (SD), ng/ml 46.4 (41.5) 54.0 (29.2) 49.1 (38.8)
Median (range), ng/ml 40.1 (0, 282.1) 53.4 (12.8, 118.1) 42.1 (0, 282.1) 0.1036
Galectin 4
N 66 21 88
Mean (SD), ng/ml 52.0 (133.0) 25.8 (85.2) 45.2 (122.6)
Median (range), ng/ml 0 (0, 868) 0 (0, 390.5) 0 (0, 868) 0.3931
Galectin 7
N 53 16 70
Mean (SD), ng/ml 60.8 (148.5) 57.8 (108.3) 59.2 (138.7)
Median (range), ng/ml 0 (0, 764.8) 0 (0, 419.6) 0 (0, 764.8) 0.8517
Galectin 8
N 68 24 93
Mean (SD), ng/ml 52.2 (102.4) 39.2 (81.0) 48.3 (96.6)
Median (range), ng/ml 4.0 (0, 578.5) 0 (0, 287.1) 3.5 (0, 578.5) 0.2921
CRP
N 59 21 80
Mean (SD), mg/L 4.6 (8.2) 10.2 (12.1) 6.1 (9.6)
Median (range), mg/L 0 (0, 35) 6 (0, 38) 0 (0, 38) 0.0472
� one patient whose disease activity could not be accurately established was also included in this analysis.
https://doi.org/10.1371/journal.pone.0227306.t004
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modulated cell behaviours [32] and inflammation development[36]. Soluble galectin-3 pro-
duced by colon epithelial cells was reported to be a strong activator of colonic lamina propria
fibroblasts by inducing cell NF-kappaB activation and IL8 secretion [12].
It should be mentioned that the disease activity used in this study was conventional clinical
indices. Patients whose sera were analysed in this study did not undergo endoscopy or faecal
collection. As clinical symptoms do not always correlate well with disease activity in IBD and
as the clinical indices are less accurate than endoscopy and faecal calprotectin analysis, further
investigations to include endoscopy and faecal calprotectin analysis will be needed to deter-
mine the possibility of using serum galectins as potential biomarkers in determining IBD dis-
ease activity. Further investigations can also include patients with gastrointestinal symptoms
Table 5. Combination of galectins-1 and -3 and CRP in active and inactive UC and CD.
UC only P value
SCCAI�2 SCCAI >2 All
Galectin 1+CRP
N 23 33 56
Mean (SD) 119.5 (246.3) 21.0 (21.1) 61.4 (164.1)
Median (range), 17.5 (0.2, 822.1) 16.1 (0, 82.3) 16.5 (0, 822.1) 0.3910
Galectin 3+CRP
N 28 37 65
Mean (SD) 45.1 (44.0) 63.1 (47.2) 55.4 (46.3)
Median (range) 28.3 (7.2, 219.8) 58.0 (8.2, 233.7) 36.2 (7.2, 233.7) 0.0219
CD only P value
HBI�5 HBI >5 All
Galectin 1+CRP
N 50 15 65
Mean (SD) 66.4 (246.6) 30.4 (24.9) 58.1 (216.6)
Median (range) 14.6 (0.3, 1308) 23 (0.6, 80.3) 15.4 (0.3, 1308) 0.1176
Galectin 3+CRP
N 59 21 80
Mean (SD) 46.3 (42.4) 62.0 (28.1) 50.4 (39.6)
Median (range) 41.4 (0, 297.1) 55.3 (20.6, 124.1) 46.8 (0, 297.1) 0.0056
https://doi.org/10.1371/journal.pone.0227306.t005
Table 6. ROC analysis of CRP alone or a combination of galectin 3 and CRP in active and inactive disease.
UC only CD only UC + CD












Galectin 3+CRP (< =
/>52)
0.637 (0.517, 0.756) [N65] 0.698 (0.580, 0.816) [80] 0.667 (0.588, 0.746) [145]
Galectin 1+CRP 0.432 (0.275, 0.589) [56] 0.634 (0.457, 0.811) [65] 0.517 (0.408, 0.625) [121]
Galectin 1+CRP (</> =
17.9)
0.488 (0.353, 0.624) [56] 0.623 (0.482, 0.765) [65] 0.541 (0.450, 0.633) [121]
Cut-off with highest correct % classification is 17.9 and 52 for galectin-1 and -3 respectively (for all IBD patients)–
hence values above relate to ROC curve for ‘CRP + galectin1 > = 17.9’ versus ‘CRP > 5’ and CRP + galectin3 > = 52’
versus ‘CRP > 5’. The numerical value for the combination of serum CRP and galectin was obtained by simply
combining the actual values.
https://doi.org/10.1371/journal.pone.0227306.t006
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such as irritable bowel syndrome and coeliac disease to truly establish the discriminatory value
of galectins. Due to the limited number of patients in each sub-group, meaningful evaluation
of the impact of disease location (e.g. ileal compared to colonic Crohn’s disease), disease dura-
tion and medications on serum galectin values was not possible in this study.
In conclusion, serum levels of galectins-1 and -3, but not galectins-2, -4, -7 and -8, are sig-
nificantly elevated in both UC and CD patients in comparison to healthy people. Although the
increased levels of these galectins are not able to separate active and inactive UC and CD, they
have the potential to be developed as biomarkers for general IBD determination.
Supporting information
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